Image credit: Yusia13/Shutterstock.com In a recent study published in eBioMedicine , researchers report that tirzepatide, a dual incretin agonist targeting receptors for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), may represent a potential therapeutic avenue for treating alcohol use disorder (AUD)
If you start with one pharmacy and later want to switch for pricing or availability reasons, discuss concentration differences with your provider to avoid inadvertent under-dosing or over-dosing during the transition
Medicares $50 Per Month GLP-1 Bridge: What You Need to Know
Weight loss achieved with Mounjaro may ultimately improve sleep quality, particularly in patients with obesity-related sleep apnoea
There is currently no established direct pharmacological link between Wegovy (semaglutide) and iron deficiency
Personal health, dosing, and consistency all affect the timeline